[en] Cancer therapy can be associated with both cardiac and vascular toxicity. Advanced multi-modality imaging can be used to stratify patient risk, identify cardiovascular injury during and after therapy, and forecast recovery. Echocardiography continues to be the mainstay in the evaluation of cardiac toxicity. Particularly, echocardiography-based strain imaging is useful for risk stratification of patients at baseline, and detection of subclinical left ventricle (LV) dysfunction during therapy. Cardiac magnetic resonance (CMR) serves a complementary role in the patient with poor echocardiographic or equilibrium radionuclide angiographic image quality or in situations where a more accurate and precise LV ejection fraction measurement is needed to inform decisions regarding discontinuation of chemotherapy. New CMR techniques like T1 and T2 mapping and positron emission tomography (PET) imaging will help us better understand the structural, pathological, and metabolic myocardial changes associated with ventricular dysfunction or release of serum biomarkers. CMR may also be helpful in the evaluation of vascular complications of cancer therapy. Stress echocardiography, stress CMR, computed tomography, and PET are excellent imaging options in the evaluation of ischemia in patients receiving therapies that could potentially cause vasospasm or accelerated atherosclerosis.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Plana, Juan Carlos
Thavendiranathan, Paaladinesh
Bucciarelli-Ducci, Chiara
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Language :
English
Title :
Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient.
Publication date :
2018
Journal title :
JACC. Cardiovascular Imaging
ISSN :
1936-878X
eISSN :
1876-7591
Publisher :
Elsevier, Netherlands
Volume :
11
Issue :
8
Pages :
1173-1186
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2018 American College of Cardiology Foundation. All rights reserved.
Moslehi, J.J., Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 (2016), 1457–1467.
Yeh, E.T., Chang, H.M., Oncocardiology—past, present, and future: a review. JAMA Cardiol 1 (2016), 1066–1072.
Abdel-Qadir, H., Austin, P.C., Lee, D.S., et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2 (2017), 88–93.
Yeh, E.T., Bickford, C.L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 (2009), 2231–2247.
Armenian, S.H., Lacchetti, C., Barac, A., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35 (2017), 893–911.
Plana, J.C., Galderisi, M., Barac, A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 (2014), 911–939.
Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16 (2015), 233–270.
Thavendiranathan, P., Grant, A.D., Negishi, T., Plana, J.C., Popovic, Z.B., Marwick, T.H., Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61 (2013), 77–84.
Ali, M.T., Yucel, E., Bouras, S., et al. Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines. J Am Soc Echocardiogr 29 (2016), 522–527.
Mousavi, N., Tan, T.C., Ali, M., Halpern, E.F., Wang, L., Scherrer-Crosbie, M., Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 16 (2015), 977–984.
Narayan, H.K., French, B., Khan, A.M., et al. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. J Am Coll Cardiol Img 9 (2016), 1131–1141.
Lancellotti, P., Nkomo, V.T., Badano, L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26 (2013), 1013–1032.
Authors/Task Force m, Windecker, S., Kolh, P., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
Plana, J.C., Mikati, I.A., Dokainish, H., et al. A randomized cross-over study for evaluation of the effect of image optimization with contrast on the diagnostic accuracy of dobutamine echocardiography in coronary artery disease the OPTIMIZE Trial. J Am Coll Cardiol Img 1 (2008), 145–152.
Goldvaser, H., Barnes, T.A., Seruga, B., et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst, 110, 2018.
Herrmann, J., Yang, E.H., Iliescu, C.A., et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133 (2016), 1272–1289.
Jaiswal, S., Natarajan, P., Silver, A.J., et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377 (2017), 111–121.
Genovese, G., Kahler, A.K., Handsaker, R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
Coombs, C.C., Zehir, A., Devlin, S.M., et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21 (2017), 374–382.
Jaiswal, S., Fontanillas, P., Flannick, J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
Huang, H., Nijjar, P.S., Misialek, J.R., et al. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 19, 2017, 34.
Drafts, B.C., Twomley, K.M., D'Agostino, R. Jr., et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. J Am Coll Cardiol Img 6 (2013), 877–885.
Melendez, G.C., Sukpraphrute, B., D'Agostino, R.B. Jr., et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. Am J Cardiol 119 (2017), 1637–1642.
Zhang, K.W., Finkelman, B.S., Gulati, G., et al. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. J Am Coll Cardiol Img 11 (2018), 1059–1068.
Santoro, C., Arpino, G., Esposito, R., et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging 18 (2017), 930–936.
Porter, T.R., Mulvagh, S.L., Abdelmoneim, S.S., et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr 31 (2018), 241–274.
Armstrong, G.T., Plana, J.C., Zhang, N., et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30 (2012), 2876–2884.
Pituskin, E., Mackey, J.R., Koshman, S., et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35 (2017), 870–877.
Jordan, J.H., D'Agostino, R.B. Jr., Hamilton, C.A., et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 7 (2014), 872–879.
Grover, S., Leong, D.P., Chakrabarty, A., et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol 168 (2013), 5465–5467.
Jordan, J.H., Sukpraphrute, B., Melendez, G.C., Jolly, M.P., D'Agostino, R.B. Jr., Hundley, W.G., Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: the need to interpret left ventricular strain with volumes. Circulation 135 (2017), 2575–2577.
Marchesseau, S., Ho, J.X., Totman, J.J., Influence of the short-axis cine acquisition protocol on the cardiac function evaluation: a reproducibility study. Eur J Radiol Open 3 (2016), 60–66.
Marcus, J.T., Gotte, M.J., DeWaal, L.K., et al. The influence of through-plane motion on left ventricular volumes measured by magnetic resonance imaging: implications for image acquisition and analysis. J Cardiovasc Magn Reson 1 (1999), 1–6.
Stohr, E.J., Gonzalez-Alonso, J., Pearson, J., et al. Dehydration reduces left ventricular filling at rest and during exercise independent of twist mechanics. J Appl Physiol 111 (2011), 891–897.
Negishi, K., Negishi, T., Hare, J.L., Haluska, B.A., Plana, J.C., Marwick, T.H., Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26 (2013), 493–498.
Stokke, T.M., Hasselberg, N.E., Smedsrud, M.K., et al. Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain. J Am Coll Cardiol 70 (2017), 942–954.
Narayan, H.K., Finkelman, B., French, B., et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-Up. Circulation 135 (2017), 1397–1412.
Farsalinos, K.E., Daraban, A.M., Unlu, S., Thomas, J.D., Badano, L.P., Voigt, J.U., Head–to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr 28 (2015), 1171–1181.
Negishi, K., Negishi, T., Agler, D.A., Plana, J.C., Marwick, T.H., Role of temporal resolution in selection of the appropriate strain technique for evaluation of subclinical myocardial dysfunction. Echocardiography 29 (2012), 334–339.
Ferreira, V.M., Piechnik, S.K., Dall'Armellina, E., et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 14, 2012, 42.
Thavendiranathan, P., Wintersperger, B.J., Flamm, S.D., Marwick, T.H., Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 6 (2013), 1080–1091.
Kellman, P., Wilson, J.R., Xue, H., et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson, 14, 2012, 64.
Oberholzer, K., Kunz, R.P., Dittrich, M., Thelen, M., [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer]. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 176 (2004), 1245–1250.
Jordan, J.H., Vasu, S., Morgan, T.M., et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging, 9, 2016, e004325.
Neilan, T.G., Coelho-Filho, O.R., Shah, R.V., et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111 (2013), 717–722.
Tham, E.B., Haykowsky, M.J., Chow, K., et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson, 15, 2013, 48.
Wadhwa, D., Fallah-Rad, N., Grenier, D., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 117 (2009), 357–364.
Fallah-Rad, N., Lytwyn, M., Fang, T., Kirkpatrick, I., Jassal, D.S., Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson, 10, 2008, 5.
Bucciarelli-Ducci, C., Azevedo, C.F., On fibrosis, prognosis, and the unique role of CMR: a paradigm shift from “bright is dead” to “bright is bad”. J Am Coll Cardiol 64 (2014), 155–157.
Asnani, A., Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Cur Oncol Rep, 20, 2018, 44.
Friedrich, M.G., Sechtem, U., Schulz-Menger, J., et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 53 (2009), 1475–1487.
Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
Bauckneht, M., Ferrarazzo, G., Fiz, F., et al. Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational (18)F-FDG PET/CT ibservation. J Nucl Med 58 (2017), 1638–1645.
Cardinale, D., Sandri, M.T., Colombo, A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109 (2004), 2749–2754.
Cardinale, D., Sandri, M.T., Martinoni, A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13 (2002), 710–715.
Cardinale, D., Sandri, M.T., Martinoni, A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36 (2000), 517–522.
Cardinale, D., Colombo, A., Torrisi, R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28 (2010), 3910–3916.
Sawaya, H., Sebag, I.A., Plana, J.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5 (2012), 596–603.
Ky, B., Putt, M., Sawaya, H., et al. Early increases in multiple biomarkes predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63 (2014), 809–816.
Di Lisi, D., Madonna, R., Zito, C., et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol Heart Vasc 227 (2017), 11–17.
Ganten, M., Boese, J.M., Leitermann, D., Semmler, W., Quantification of aortic elasticity: development and experimental validation of a method using computed tomography. Eur Radiol 15 (2005), 2506–2512.
Cardinale, D., Colombo, A., Lamantia, G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55 (2010), 213–220.
Fei, H.W., Ali, M.T., Tan, T.C., et al. Left ventricular global longitudinal strain in HER-2+ breast cancer patients treated with anthracyclines and trastuzumab who develop cardiotoxicity is associated with subsequent recovery of left ventricular ejection fraction. Echocardiography 33 (2016), 519–526.
Cardinale, D., Colombo, A., Bacchiani, G., et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 (2015), 1981–1988.
Oliveira, G.H., Mukerji, S., Hernandez, A.V., et al. Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol 113 (2014), 1893–1898.
Armstrong, G.T., Joshi, V.M., Ness, K.K., et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study. J Am Coll Cardiol 65 (2015), 2511–2522.
Murbraech, K., Holte, E., Broch, K., et al. Impaired right ventricular function in long–term lymphoma survivors. J Am Soc Echocardiogr 29 (2016), 528–536.
Chang, W.T., Shih, J.Y., Feng, Y.H., et al. The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer. Acta Cardiologica Sinica 32 (2016), 550–559.
Verhaert, D., Gabriel, R.S., Johnston, D., Lytle, B.W., Desai, M.Y., Klein, A.L., The role of multimodality imaging in the management of pericardial disease. Circ Cardiovasc Imaging 3 (2010), 333–343.
Grover, S., Lou, P.W., Bradbrook, C., et al. Early and late changes in markers of aortic stiffness with breast cancer therapy. Intern Med J 45 (2015), 140–147.
Ruble, K., Davis, C.L., Han, H.R., Endothelial health in childhood acute lymphoid leukemia survivors: pilot evaluation with peripheral artery tonometry. J Pediatr Hematol Oncol 37 (2015), 117–120.
Krystal, J.I., Reppucci, M., Mayr, T., Fish, J.D., Sethna, C., Arterial stiffness in childhood cancer survivors. Pediatr Blood Cancer 62 (2015), 1832–1837.
Vallerio, P., Sarno, L., Stucchi, M., et al. Long-term effects of radiotherapy on arterial stiffness in breast cancer women. Am J Cardiol 118 (2016), 771–776.
